![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ANAPC1 |
Gene summary for ANAPC1 |
![]() |
Gene information | Species | Human | Gene symbol | ANAPC1 | Gene ID | 64682 |
Gene name | anaphase promoting complex subunit 1 | |
Gene Alias | APC1 | |
Cytomap | 2q13 | |
Gene Type | protein-coding | GO ID | GO:0000070 | UniProtAcc | Q9H1A4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
64682 | ANAPC1 | LZE4T | Human | Esophagus | ESCC | 2.10e-02 | 8.22e-02 | 0.0811 |
64682 | ANAPC1 | LZE7T | Human | Esophagus | ESCC | 3.13e-10 | 2.85e-01 | 0.0667 |
64682 | ANAPC1 | LZE8T | Human | Esophagus | ESCC | 1.30e-05 | 1.18e-01 | 0.067 |
64682 | ANAPC1 | LZE20T | Human | Esophagus | ESCC | 1.27e-02 | 1.37e-01 | 0.0662 |
64682 | ANAPC1 | LZE24T | Human | Esophagus | ESCC | 8.74e-13 | 2.99e-01 | 0.0596 |
64682 | ANAPC1 | P1T-E | Human | Esophagus | ESCC | 4.00e-06 | 2.46e-01 | 0.0875 |
64682 | ANAPC1 | P2T-E | Human | Esophagus | ESCC | 2.86e-20 | 2.52e-01 | 0.1177 |
64682 | ANAPC1 | P4T-E | Human | Esophagus | ESCC | 6.09e-22 | 5.61e-01 | 0.1323 |
64682 | ANAPC1 | P5T-E | Human | Esophagus | ESCC | 6.71e-12 | 2.39e-01 | 0.1327 |
64682 | ANAPC1 | P8T-E | Human | Esophagus | ESCC | 1.85e-18 | 2.72e-01 | 0.0889 |
64682 | ANAPC1 | P9T-E | Human | Esophagus | ESCC | 4.03e-13 | 3.58e-01 | 0.1131 |
64682 | ANAPC1 | P10T-E | Human | Esophagus | ESCC | 1.15e-45 | 6.87e-01 | 0.116 |
64682 | ANAPC1 | P11T-E | Human | Esophagus | ESCC | 4.42e-03 | 2.02e-01 | 0.1426 |
64682 | ANAPC1 | P12T-E | Human | Esophagus | ESCC | 9.67e-18 | 3.44e-01 | 0.1122 |
64682 | ANAPC1 | P15T-E | Human | Esophagus | ESCC | 3.86e-23 | 4.04e-01 | 0.1149 |
64682 | ANAPC1 | P16T-E | Human | Esophagus | ESCC | 4.67e-20 | 2.61e-01 | 0.1153 |
64682 | ANAPC1 | P17T-E | Human | Esophagus | ESCC | 3.93e-04 | 2.65e-01 | 0.1278 |
64682 | ANAPC1 | P19T-E | Human | Esophagus | ESCC | 2.11e-07 | 3.56e-01 | 0.1662 |
64682 | ANAPC1 | P20T-E | Human | Esophagus | ESCC | 7.41e-13 | 2.92e-01 | 0.1124 |
64682 | ANAPC1 | P21T-E | Human | Esophagus | ESCC | 1.61e-29 | 5.48e-01 | 0.1617 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00104989 | Breast | Precancer | proteasomal protein catabolic process | 58/1080 | 490/18723 | 1.54e-07 | 8.05e-06 | 58 |
GO:00431619 | Breast | Precancer | proteasome-mediated ubiquitin-dependent protein catabolic process | 42/1080 | 412/18723 | 2.49e-04 | 3.72e-03 | 42 |
GO:001049814 | Breast | IDC | proteasomal protein catabolic process | 75/1434 | 490/18723 | 5.59e-09 | 4.41e-07 | 75 |
GO:004316114 | Breast | IDC | proteasome-mediated ubiquitin-dependent protein catabolic process | 57/1434 | 412/18723 | 9.55e-06 | 2.68e-04 | 57 |
GO:00330445 | Breast | IDC | regulation of chromosome organization | 26/1434 | 187/18723 | 2.22e-03 | 2.06e-02 | 26 |
GO:00073465 | Breast | IDC | regulation of mitotic cell cycle | 51/1434 | 457/18723 | 4.30e-03 | 3.35e-02 | 51 |
GO:00459315 | Breast | IDC | positive regulation of mitotic cell cycle | 18/1434 | 121/18723 | 4.90e-03 | 3.73e-02 | 18 |
GO:001049824 | Breast | DCIS | proteasomal protein catabolic process | 75/1390 | 490/18723 | 1.44e-09 | 1.40e-07 | 75 |
GO:004316124 | Breast | DCIS | proteasome-mediated ubiquitin-dependent protein catabolic process | 57/1390 | 412/18723 | 3.76e-06 | 1.16e-04 | 57 |
GO:000734612 | Breast | DCIS | regulation of mitotic cell cycle | 52/1390 | 457/18723 | 1.38e-03 | 1.43e-02 | 52 |
GO:003304412 | Breast | DCIS | regulation of chromosome organization | 26/1390 | 187/18723 | 1.44e-03 | 1.47e-02 | 26 |
GO:004593112 | Breast | DCIS | positive regulation of mitotic cell cycle | 19/1390 | 121/18723 | 1.47e-03 | 1.49e-02 | 19 |
GO:00447724 | Breast | DCIS | mitotic cell cycle phase transition | 46/1390 | 424/18723 | 6.16e-03 | 4.39e-02 | 46 |
GO:001049810 | Cervix | CC | proteasomal protein catabolic process | 111/2311 | 490/18723 | 8.98e-11 | 1.58e-08 | 111 |
GO:004316110 | Cervix | CC | proteasome-mediated ubiquitin-dependent protein catabolic process | 91/2311 | 412/18723 | 1.65e-08 | 1.25e-06 | 91 |
GO:00002097 | Cervix | CC | protein polyubiquitination | 58/2311 | 236/18723 | 1.57e-07 | 7.41e-06 | 58 |
GO:00447725 | Cervix | CC | mitotic cell cycle phase transition | 89/2311 | 424/18723 | 2.70e-07 | 1.12e-05 | 89 |
GO:00457876 | Cervix | CC | positive regulation of cell cycle | 66/2311 | 313/18723 | 7.78e-06 | 1.81e-04 | 66 |
GO:00073466 | Cervix | CC | regulation of mitotic cell cycle | 88/2311 | 457/18723 | 1.26e-05 | 2.60e-04 | 88 |
GO:19019903 | Cervix | CC | regulation of mitotic cell cycle phase transition | 63/2311 | 299/18723 | 1.27e-05 | 2.60e-04 | 63 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0411023 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
hsa05166211 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
hsa041146 | Esophagus | ESCC | Oocyte meiosis | 77/4205 | 131/8465 | 2.19e-02 | 4.80e-02 | 2.46e-02 | 77 |
hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0411033 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
hsa05166310 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
hsa0411411 | Esophagus | ESCC | Oocyte meiosis | 77/4205 | 131/8465 | 2.19e-02 | 4.80e-02 | 2.46e-02 | 77 |
hsa0412041 | Liver | HCC | Ubiquitin mediated proteolysis | 110/4020 | 142/8465 | 1.67e-13 | 3.74e-12 | 2.08e-12 | 110 |
hsa041102 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
hsa0516622 | Liver | HCC | Human T-cell leukemia virus 1 infection | 139/4020 | 222/8465 | 3.17e-06 | 2.79e-05 | 1.55e-05 | 139 |
hsa0412051 | Liver | HCC | Ubiquitin mediated proteolysis | 110/4020 | 142/8465 | 1.67e-13 | 3.74e-12 | 2.08e-12 | 110 |
hsa041103 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
hsa0516632 | Liver | HCC | Human T-cell leukemia virus 1 infection | 139/4020 | 222/8465 | 3.17e-06 | 2.79e-05 | 1.55e-05 | 139 |
hsa0516630 | Oral cavity | OSCC | Human T-cell leukemia virus 1 infection | 150/3704 | 222/8465 | 3.68e-13 | 7.26e-12 | 3.70e-12 | 150 |
hsa05166113 | Oral cavity | OSCC | Human T-cell leukemia virus 1 infection | 150/3704 | 222/8465 | 3.68e-13 | 7.26e-12 | 3.70e-12 | 150 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ANAPC1 | SNV | Missense_Mutation | novel | c.1873N>G | p.Ile625Val | p.I625V | Q9H1A4 | protein_coding | tolerated(0.28) | benign(0) | TCGA-DD-AAW2-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
ANAPC1 | SNV | Missense_Mutation | c.4618N>T | p.Arg1540Cys | p.R1540C | Q9H1A4 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-G3-A7M6-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
ANAPC1 | SNV | Missense_Mutation | novel | c.1844N>G | p.Ser615Cys | p.S615C | Q9H1A4 | protein_coding | tolerated(0.16) | probably_damaging(0.97) | TCGA-44-2662-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Other, specify in notesGSK Mage Vaccine Study | rec | PD |
ANAPC1 | SNV | Missense_Mutation | c.1702N>A | p.Asp568Asn | p.D568N | Q9H1A4 | protein_coding | tolerated(0.51) | benign(0.111) | TCGA-44-7667-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ANAPC1 | SNV | Missense_Mutation | rs779157640 | c.4798C>T | p.Arg1600Trp | p.R1600W | Q9H1A4 | protein_coding | deleterious(0) | possibly_damaging(0.698) | TCGA-44-8117-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ANAPC1 | SNV | Missense_Mutation | novel | c.3767G>T | p.Gly1256Val | p.G1256V | Q9H1A4 | protein_coding | deleterious(0) | possibly_damaging(0.831) | TCGA-53-A4EZ-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | CR |
ANAPC1 | SNV | Missense_Mutation | novel | c.3766G>T | p.Gly1256Cys | p.G1256C | Q9H1A4 | protein_coding | deleterious(0) | probably_damaging(0.936) | TCGA-53-A4EZ-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | CR |
ANAPC1 | SNV | Missense_Mutation | novel | c.2571G>T | p.Met857Ile | p.M857I | Q9H1A4 | protein_coding | tolerated(0.39) | benign(0.001) | TCGA-55-6985-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ANAPC1 | SNV | Missense_Mutation | novel | c.1358G>T | p.Arg453Leu | p.R453L | Q9H1A4 | protein_coding | tolerated(0.25) | probably_damaging(0.966) | TCGA-55-7907-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
ANAPC1 | SNV | Missense_Mutation | rs755821664 | c.5086G>T | p.Val1696Phe | p.V1696F | Q9H1A4 | protein_coding | tolerated(0.44) | benign(0.303) | TCGA-78-7166-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |